FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016101761> ?p ?o ?g. }

• W2016101761 endingPage "890" @default.
• W2016101761 startingPage "883" @default.
• W2016101761 abstract "Multiple myeloma (MM) is an incurable malignancy of plasma cells. Although multiple myeloma patients often respond to initial therapy, the majority of patients will relapse with disease that is refractory to further drug treatment. Thus, new therapeutic strategies are needed. One common mechanism of acquired drug resistance involves a reduction in the expression or function of the drug target. We hypothesized that the cytotoxic activity of topoisomerase II (topo II) poisons could be enhanced, and drug resistance overcome, by increasing the expression and activity of the drug target, topo II in myeloma cells. To test this hypothesis, we evaluated the cytotoxicity of the anthracene-containing topo II poison, ethonafide (AMP-53/6-ethoxyazonafide), in combination with the proteasome inhibitor bortezomib (PS-341/Velcade). Combination drug activity studies were done in 8226/S myeloma cells and its drug resistant subclone, 8226/Dox1V. We found that a 24-h treatment of cells with bortezomib maximally increased topo IIα protein expression and activity, and consistently increased the cytotoxicity of ethonafide in the 8226/S and 8226/Dox1V cell lines. This increase in cytotoxicity corresponded to an increase in DNA double-strand breaks, as measured by the neutral comet assay. Therefore, increasing topo IIα expression through inhibition of proteasomal degradation increased DNA double-strand breaks and enhanced the cytotoxicity of the topo II poison ethonafide. These data suggest that bortezomib-mediated stabilization of topo IIα expression may potentiate the cytotoxic activity of topo II poisons and thereby, provide a strategy to circumvent drug resistance." @default.
• W2016101761 created "2016-06-24" @default.
• W2016101761 creator A5004500249 @default.
• W2016101761 creator A5007377552 @default.
• W2016101761 creator A5029302769 @default.
• W2016101761 creator A5070130751 @default.
• W2016101761 creator A5071810244 @default.
• W2016101761 date "2008-02-01" @default.
• W2016101761 modified "2023-10-16" @default.
• W2016101761 title "Proteasomal inhibition stabilizes topoisomerase IIα protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide)" @default.
• W2016101761 cites W1968557197 @default.
• W2016101761 cites W1973179542 @default.
• W2016101761 cites W1992978957 @default.
• W2016101761 cites W2013294222 @default.
• W2016101761 cites W2019387053 @default.
• W2016101761 cites W2025491667 @default.
• W2016101761 cites W2027348595 @default.
• W2016101761 cites W2031242841 @default.
• W2016101761 cites W2043510752 @default.
• W2016101761 cites W2067653691 @default.
• W2016101761 cites W2070243196 @default.
• W2016101761 cites W2074341633 @default.
• W2016101761 cites W2089302745 @default.
• W2016101761 cites W2092638438 @default.
• W2016101761 cites W2127236494 @default.
• W2016101761 cites W2150123812 @default.
• W2016101761 cites W2158076415 @default.
• W2016101761 cites W2160972799 @default.
• W2016101761 cites W2167526365 @default.
• W2016101761 cites W2195560519 @default.
• W2016101761 cites W2292808816 @default.
• W2016101761 doi "https://doi.org/10.1016/j.bcp.2007.10.026" @default.
• W2016101761 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2271051" @default.
• W2016101761 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18062937" @default.
• W2016101761 hasPublicationYear "2008" @default.
• W2016101761 type Work @default.
• W2016101761 sameAs 2016101761 @default.
• W2016101761 citedByCount "16" @default.
• W2016101761 countsByYear W20161017612012 @default.
• W2016101761 countsByYear W20161017612013 @default.
• W2016101761 countsByYear W20161017612014 @default.
• W2016101761 countsByYear W20161017612016 @default.
• W2016101761 countsByYear W20161017612017 @default.
• W2016101761 countsByYear W20161017612018 @default.
• W2016101761 countsByYear W20161017612020 @default.
• W2016101761 countsByYear W20161017612023 @default.
• W2016101761 crossrefType "journal-article" @default.
• W2016101761 hasAuthorship W2016101761A5004500249 @default.
• W2016101761 hasAuthorship W2016101761A5007377552 @default.
• W2016101761 hasAuthorship W2016101761A5029302769 @default.
• W2016101761 hasAuthorship W2016101761A5070130751 @default.
• W2016101761 hasAuthorship W2016101761A5071810244 @default.
• W2016101761 hasBestOaLocation W20161017612 @default.
• W2016101761 hasConcept C109316439 @default.
• W2016101761 hasConcept C114851261 @default.
• W2016101761 hasConcept C147897179 @default.
• W2016101761 hasConcept C154317977 @default.
• W2016101761 hasConcept C185592680 @default.
• W2016101761 hasConcept C202751555 @default.
• W2016101761 hasConcept C203014093 @default.
• W2016101761 hasConcept C27740335 @default.
• W2016101761 hasConcept C2776364478 @default.
• W2016101761 hasConcept C2777478702 @default.
• W2016101761 hasConcept C2778367456 @default.
• W2016101761 hasConcept C2780035454 @default.
• W2016101761 hasConcept C502942594 @default.
• W2016101761 hasConcept C552990157 @default.
• W2016101761 hasConcept C55493867 @default.
• W2016101761 hasConcept C86803240 @default.
• W2016101761 hasConcept C89423630 @default.
• W2016101761 hasConcept C98274493 @default.
• W2016101761 hasConceptScore W2016101761C109316439 @default.
• W2016101761 hasConceptScore W2016101761C114851261 @default.
• W2016101761 hasConceptScore W2016101761C147897179 @default.
• W2016101761 hasConceptScore W2016101761C154317977 @default.
• W2016101761 hasConceptScore W2016101761C185592680 @default.
• W2016101761 hasConceptScore W2016101761C202751555 @default.
• W2016101761 hasConceptScore W2016101761C203014093 @default.
• W2016101761 hasConceptScore W2016101761C27740335 @default.
• W2016101761 hasConceptScore W2016101761C2776364478 @default.
• W2016101761 hasConceptScore W2016101761C2777478702 @default.
• W2016101761 hasConceptScore W2016101761C2778367456 @default.
• W2016101761 hasConceptScore W2016101761C2780035454 @default.
• W2016101761 hasConceptScore W2016101761C502942594 @default.
• W2016101761 hasConceptScore W2016101761C552990157 @default.
• W2016101761 hasConceptScore W2016101761C55493867 @default.
• W2016101761 hasConceptScore W2016101761C86803240 @default.
• W2016101761 hasConceptScore W2016101761C89423630 @default.
• W2016101761 hasConceptScore W2016101761C98274493 @default.
• W2016101761 hasIssue "4" @default.
• W2016101761 hasLocation W20161017611 @default.
• W2016101761 hasLocation W20161017612 @default.
• W2016101761 hasLocation W20161017613 @default.
• W2016101761 hasLocation W20161017614 @default.
• W2016101761 hasOpenAccess W2016101761 @default.
• W2016101761 hasPrimaryLocation W20161017611 @default.
• W2016101761 hasRelatedWork W1987710106 @default.
• W2016101761 hasRelatedWork W2063424779 @default.

• next